Androgenic AlopeciaKDKR26NCT07810504
Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy
A study testing Scalp Stimulating Serum and Red Light Hair Growth Cap in people with Androgenic Alopecia and Female Pattern Hair Loss, run by K. Kay Durairaj, MD, FACS, A Medical Corporation at 1 site in United States.
Trial summary
This single-center, prospective, randomized, placebo-controlled interventional study will evaluate the safety and efficacy of KeraFactor scalp-stimulating solution and the Revian Red wireless smart cap, alone and in combination, for the treatment of female androgenic alopecia. Read more about this study
- Who is it for?
- Ages 35 to 55 years, women only
- Conditions the study is for
- Androgenic Alopecia, Female Pattern Hair Loss, Hair Loss
- What is being tested?
- Scalp Stimulating Serum and Red Light Hair Growth Cap
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Mar 2026to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 55 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Female participants aged 35 to 55 years, inclusive.
- Clinically diagnosed with androgenic alopecia.
- Fitzpatrick Skin Types I-VI.
- Willingness to undergo baseline laboratory screening, including CBC, TSH, iron/TIBC, 25-hydroxyvitamin D, ferritin, free testosterone, total testosterone, estradiol (E2), and FSH, to confirm eligibility and stratification status.
- Generally healthy individuals with no significant dermatological conditions affecting the scalp, such as eczema, psoriasis, or folliculitis, that could interfere with treatment assessment.
- Willingness to maintain a consistent hair care routine and refrain from new hair treatments, supplements, or grooming practices that could confound study results.
Show all 13Show fewer
- Willingness and ability to provide recent laboratory results to establish baseline metabolic parameters.
- Participants must have a smartphone or tablet that operates on iOS version 11.0 or higher and/or Android 9.0 or higher, access to the Apple App Store or Google Play to download the REVIAN app, and internet or wireless network connectivity.
- Commitment to avoid hair dryer use for at least 48 hours before and after each office visit.
- Commitment to avoid hair extensions for at least 6 months prior to and throughout the study duration.
- Ability and willingness to adhere to the study protocol, including scheduled visits and assessments.
- Willingness to allow trichoscopic and photographic documentation of the scalp and hair.
- Ability and willingness to provide written informed consent after being fully informed about the study's nature, purpose, procedures, potential risks, and benefits.
Who cannot join
- Presence of autoimmune or pathologic causes of hair loss, such as alopecia areata or lichen planus.
- Active scalp disorders or infections, such as eczema, psoriasis, seborrheic dermatitis, or folliculitis.
- Clinically significant abnormalities in baseline screening labs, including CBC, TSH, iron/TIBC, 25-hydroxyvitamin D, ferritin, free testosterone, total testosterone, E2, and FSH, that fall outside satisfactory ranges for hair growth or indicate an underlying medical pathology, such as iron deficiency anemia or thyroid dysfunction.
- History of hypersensitivity to any components of KeraFactor scalp-stimulating solution.
- Presence of a medical condition that makes the skin sensitive to sun or light, or use of photosensitizing medications, shampoos, lotions, or other therapies that sensitize the skin to light.
- Medical conditions or medications known to significantly affect hair growth, including uncontrolled thyroid disorders, anemia, cancer, chemotherapy, spironolactone, 5-alpha-reductase inhibitors, or cyproterone.
Show all 19Show fewer
- Active use of GLP-1 receptor agonists, such as Ozempic, Wegovy, Mounjaro, Zepbound, or similar medications.
- Active use of topical treatments for hair regrowth, such as minoxidil or finasteride.
- Pregnant, breastfeeding, or planning to become pregnant during the study.
- Unrealistic expectations or psychological conditions that may impact study compliance or satisfaction.
- Continual use of red-light or low-level laser therapy outside of study requirements.
- Recent initiation of topical hair regrowth treatments, such as minoxidil or finasteride.
- Continual use of minoxidil, finasteride, or other hair regrowth treatments.
- Any active cancer or cancer diagnosis.
- Active smoking habit.
- History of hair transplant procedures.
- Significant scalp scarring or structural anomalies in treatment zones.
- Recent major surgeries or medical interventions within the last 3 months.
- History of prolonged or repeated mechanical tension on the hair or scalp, such as tight hairstyles contributing to traction alopecia.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
K. Kay Durairaj, M.D., A Medical Corp.
Pasadena, California, 91105
Kalpna K Durairaj, MD, 6263167033, drkay@beautybydrkay.com
About this study
Official title: Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy: A Randomized, Placebo Controlled Study
This single-center, prospective, randomized, placebo-controlled interventional study will evaluate the safety and efficacy of KeraFactor scalp-stimulating solution and the Revian Red wireless smart cap, alone and in combination, for the treatment of female androgenic alopecia. Forty female subjects aged 35 to 55 with clinically diagnosed androgenic alopecia will be randomized into four treatment arms and followed for 24 weeks. The primary objective is to determine whether combination therapy produces greater improvement in hair growth from baseline to 6 months compared with solution alone, device alone, or placebo. Secondary outcomes include changes in hair density, hair fiber diameter, interfollicular distance, terminal-to-vellus hair ratio, patient satisfaction, and safety/tolerability.
Read the detailed description
Female pattern hair loss is a common progressive condition characterized by follicular miniaturization, reduced hair density, and altered anagen-to-telogen ratios. Available treatments may provide partial or inconsistent results, creating a need for additional non-surgical, low-maintenance therapeutic approaches.
This study is designed to evaluate a dual-modality treatment approach using KeraFactor scalp-stimulating solution and the Revian Red wireless smart cap. Participants will be randomized in a 1:1:1:1 allocation to one of four groups: scalp-stimulating solution alone, placebo solution plus Revian Red cap, scalp-stimulating solution plus Revian Red cap, or placebo solution alone. The active and placebo solutions will be double-blinded, while device assignment will be open-label. Outcome assessors will remain blinded to treatment assignment to the extent feasible.
Screening will include medical history, scalp examination, and laboratory testing, including CBC, TSH, iron/TIBC, 25-hydroxyvitamin D, ferritin, free testosterone, total testosterone, estradiol, and FSH. Menopausal status will be used for stratification during randomization. Eligible subjects will complete in-office assessments at baseline, Week 12, and Week 24.
Study assessments will include standardized clinical photography, high-resolution DSLR photography, AI HairMetrix analysis, physician and patient Global Aesthetic Improvement Scale ratings, Ludwig Scale assessment, patient satisfaction questionnaires, adherence review, and adverse event monitoring. Quantitative endpoints will include hair density, hair fiber diameter, follicular unit composition, average hairs per follicular unit, interfollicular distance, and terminal-to-vellus hair ratio.
Subjects who complete the 24-week study will receive one Revian Red cap device and a six-month supply of KeraFactor serum after completion of the controlled study period.
- Conditions
- Androgenic Alopecia, Female Pattern Hair Loss, Hair Loss
- Being tested
- Scalp Stimulating Serum, Red Light Hair Growth Cap, Placebo scalp-stimulating serum
- Keywords
- Red Light Therapy, Low-level Light Therapy, Hair Regrowth
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Scalp Stimulating SerumOther
Also called KeraFactor Scalp Stimulating Serum, KeraFactor Serum, KeraFactor
Participants assigned to receive the active scalp-stimulating serum will apply one full dropper directly to the scalp once daily and massage it in gently. The product should not be rinsed off. In the combination treatment arm, the serum will be applied immediately before use of the Revian Red Cap.
Red Light Hair Growth CapDevice
Also called Revian Red Hair Growth System, Revian Red Cap, Revian Red Wireless Smart Cap Device
Participants assigned to use the Revian Red Cap will use the device once daily for 10 minutes at a convenient time. The device should be used indoors or in a cool, dry area and only on dry or towel-dried hair. Study staff will assist with unboxing, app registration, and device training at the baseline visit. Device use will be logged through the Revian app.
Placebo scalp-stimulating serumOther
Also called Placebo scalp serum, Placebo solution
Participants assigned to receive placebo serum will apply one full dropper directly to the scalp once daily and massage it in gently. The placebo product should not be rinsed off. The placebo serum will be identical in appearance and packaging to the active serum and labeled with coded identifiers to maintain blinding.
| Study group | Role | What they receive |
|---|---|---|
| Scalp Stimulating Serum Only | Active comparator | Participants assigned to this arm will apply KeraFactor scalp-stimulating solution directly to the scalp once daily and massage it in gently. Participants in this arm will not use the Revian Red Cap during the controlled study period. Receives: Other: Scalp Stimulating Serum |
| Placebo Solution + Revian Red Cap | Active comparator | Participants assigned to this arm will apply placebo scalp-stimulating solution directly to the scalp once daily and massage it in gently. Participants will also use the Revian Red Cap once daily for 10 minutes according to device instructions. Receives: Device: Red Light Hair Growth Cap; Other: Placebo scalp-stimulating serum |
| Scalp Stimulating Serum + Revian Red Cap | Experimental | Participants assigned to this arm will apply KeraFactor scalp-stimulating solution directly to the scalp once daily and massage it in gently. Immediately after application, participants will use the Revian Red Cap once daily for 10 minutes according to device instructions. Receives: Other: Scalp Stimulating Serum; Device: Red Light Hair Growth Cap |
| Placebo Comparator | Placebo comparator | Participants assigned to this arm will apply placebo scalp-stimulating solution directly to the scalp once daily and massage it in gently. Participants in this arm will not use the Revian Red Cap during the controlled study period. Receives: Other: Placebo scalp-stimulating serum |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hair Density
Change in hair density, measured as hairs per cm², using AI HairMetrix analysis. Measurements will be compared from baseline to follow-up visits across treatment arms.
Measured: Baseline to 6 months
Hair Fiber Diameter
Change in average hair fiber diameter, measured in micrometers, using AI HairMetrix analysis. Measurements will be compared from baseline to follow-up visits across treatment arms.
Measured: Baseline to 6 months
Interfollicular Distance
Change in interfollicular distance using AI HairMetrix analysis. Measurements will be compared from baseline to follow-up visits across treatment arms.
Measured: Baseline to 6 months
Terminal-to-Vellus Hair Ratio
Change in terminal-to-vellus hair ratio using AI HairMetrix analysis. Measurements will be compared from baseline to follow-up visits across treatment arms.
Measured: Baseline to 6 months
Secondary outcomes (4)
Ludwig-Savin Scale for Women
The participant will be rated at each live assessment. The photonumeric scale classifies female-pattern hair loss into stages (I-1, I-2, I-3, I-4, II-1, II-2, and frontal) of increasing crown balding, in addition to a special subcategory to detect frontal anterior recession.
Measured: Baseline to 6 months
Hair Life Quality Index
A 10-question skin health index modified to asses how severely hair and scalp problems affect a a patient's life over the previous week. Responses to each question may vary between the following choices: very much, a lot, a little, not at all, not relevant.
Measured: Baseline to 6 months
Hair-Q: Satisfaction with Hair
A 14-item patient-reported outcome measure used to evaluate patient satisfaction with hair appearance and treatments. Responses to each question may vary between the following choices: 1-very dissatisfied, 2-somewhat dissatisfied, 3-somewhat satisfied, 4-very satisfied.
Measured: Baseline to 6 months
Incidence and Severity of Adverse Events
Safety and tolerability will be assessed by monitoring the incidence, severity, and type of adverse events throughout the study. Adverse events will be categorized as treatment-related or treatment-unrelated and classified according to CTCAE criteria, with attention to local skin reactions, systemic reactions, and neurological symptoms.
Measured: Baseline through Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2026
- Study start17 Mar 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Androgenic AlopeciaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- Participants will be randomized in a 1:1:1:1 allocation to one of four treatment arms evaluating two intervention variables: scalp-stimulating solution versus placebo solution, and Revian Red Cap use versus no cap use. The four arms include scalp-stimulating solution alone, placebo solution plus Revian Red Cap, scalp-stimulating solution plus Revian Red Cap, and placebo solution alone.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- K. Kay Durairaj, MD, FACS, A Medical Corporation
- Sponsor type
- University, hospital or other
- Collaborators
- KeraFactor by SkinQRI, REVIAN, Inc.
- Responsible party
- Principal investigator, Kalpna Kay Durairaj, MD, FACS, K. Kay Durairaj, MD, FACS, A Medical Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07810504
- Sponsor's protocol ID
- KDKR26
- Acronym
- KDKR26
- Status last verified
- Sep 2026
- First submitted
- 13 Jul 2026
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy: A Randomized, Placebo Controlled Study
- ClinicalTrials.gov ID
- NCT07810504
- Acronym / sponsor ID
- KDKR26 / KDKR26
- Conditions
- Androgenic Alopecia, Female Pattern Hair Loss, Hair Loss
- Keywords
- Red Light Therapy, Low-level Light Therapy, Hair Regrowth
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- K. Kay Durairaj, MD, FACS, A Medical CorporationUniversity, hospital or other
- Collaborators
- KeraFactor by SkinQRI, REVIAN, Inc.
- Study start
- 17 Mar 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 9 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single-center, prospective, randomized, placebo-controlled interventional study will evaluate the safety and efficacy of KeraFactor scalp-stimulating solution and the Revian Red wireless smart cap, alone and in combination, for the treatment of female androgenic alopecia. Forty female subjects aged 35 to 55 with clinically diagnosed androgenic alopecia will be randomized into four treatment arms and followed for 24 weeks. The primary objective is to determine whether combination therapy produces greater improvement in hair growth from baseline to 6 months compared with solution alone, device alone, or placebo. Secondary outcomes include changes in hair density, hair fiber diameter, interfollicular distance, terminal-to-vellus hair ratio, patient satisfaction, and safety/tolerability.
Detailed description
Female pattern hair loss is a common progressive condition characterized by follicular miniaturization, reduced hair density, and altered anagen-to-telogen ratios. Available treatments may provide partial or inconsistent results, creating a need for additional non-surgical, low-maintenance therapeutic approaches.
This study is designed to evaluate a dual-modality treatment approach using KeraFactor scalp-stimulating solution and the Revian Red wireless smart cap. Participants will be randomized in a 1:1:1:1 allocation to one of four groups: scalp-stimulating solution alone, placebo solution plus Revian Red cap, scalp-stimulating solution plus Revian Red cap, or placebo solution alone. The active and placebo solutions will be double-blinded, while device assignment will be open-label. Outcome assessors will remain blinded to treatment assignment to the extent feasible.
Screening will include medical history, scalp examination, and laboratory testing, including CBC, TSH, iron/TIBC, 25-hydroxyvitamin D, ferritin, free testosterone, total testosterone, estradiol, and FSH. Menopausal status will be used for stratification during randomization. Eligible subjects will complete in-office assessments at baseline, Week 12, and Week 24.
Study assessments will include standardized clinical photography, high-resolution DSLR photography, AI HairMetrix analysis, physician and patient Global Aesthetic Improvement Scale ratings, Ludwig Scale assessment, patient satisfaction questionnaires, adherence review, and adverse event monitoring. Quantitative endpoints will include hair density, hair fiber diameter, follicular unit composition, average hairs per follicular unit, interfollicular distance, and terminal-to-vellus hair ratio.
Subjects who complete the 24-week study will receive one Revian Red cap device and a six-month supply of KeraFactor serum after completion of the controlled study period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 4
- Model description
- Participants will be randomized in a 1:1:1:1 allocation to one of four treatment arms evaluating two intervention variables: scalp-stimulating solution versus placebo solution, and Revian Red Cap use versus no cap use. The four arms include scalp-stimulating solution alone, placebo solution plus Revian Red Cap, scalp-stimulating solution plus Revian Red Cap, and placebo solution alone.
| Arm | Type | Receives |
|---|---|---|
| Scalp Stimulating Serum Only | Active comparator | Other: Scalp Stimulating SerumParticipants assigned to this arm will apply KeraFactor scalp-stimulating solution directly to the scalp once daily and massage it in gently. Participants in this arm will not use the Revian Red Cap during the controlled study period. |
| Placebo Solution + Revian Red Cap | Active comparator | Device: Red Light Hair Growth Cap, Other: Placebo scalp-stimulating serumParticipants assigned to this arm will apply placebo scalp-stimulating solution directly to the scalp once daily and massage it in gently. Participants will also use the Revian Red Cap once daily for 10 minutes according to device instructions. |
| Scalp Stimulating Serum + Revian Red Cap | Experimental | Other: Scalp Stimulating Serum, Device: Red Light Hair Growth CapParticipants assigned to this arm will apply KeraFactor scalp-stimulating solution directly to the scalp once daily and massage it in gently. Immediately after application, participants will use the Revian Red Cap once daily for 10 minutes according to device instructions. |
| Placebo Comparator | Placebo comparator | Other: Placebo scalp-stimulating serumParticipants assigned to this arm will apply placebo scalp-stimulating solution directly to the scalp once daily and massage it in gently. Participants in this arm will not use the Revian Red Cap during the controlled study period. |
Who may qualify
- Ages
- 35 to 55 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (13 listed)
- Female participants aged 35 to 55 years, inclusive.
- Clinically diagnosed with androgenic alopecia.
- Fitzpatrick Skin Types I-VI.
- Willingness to undergo baseline laboratory screening, including CBC, TSH, iron/TIBC, 25-hydroxyvitamin D, ferritin, free testosterone, total testosterone, estradiol (E2), and FSH, to confirm eligibility and stratification status.
- Generally healthy individuals with no significant dermatological conditions affecting the scalp, such as eczema, psoriasis, or folliculitis, that could interfere with treatment assessment.
Key exclusion criteria (19 listed)
- Presence of autoimmune or pathologic causes of hair loss, such as alopecia areata or lichen planus.
- Active scalp disorders or infections, such as eczema, psoriasis, seborrheic dermatitis, or folliculitis.
- Clinically significant abnormalities in baseline screening labs, including CBC, TSH, iron/TIBC, 25-hydroxyvitamin D, ferritin, free testosterone, total testosterone, E2, and FSH, that fall outside satisfactory ranges for hair growth or indicate an underlying medical pathology, such as iron deficiency anemia or thyroid dysfunction.
- History of hypersensitivity to any components of KeraFactor scalp-stimulating solution.
- Presence of a medical condition that makes the skin sensitive to sun or light, or use of photosensitizing medications, shampoos, lotions, or other therapies that sensitize the skin to light.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Scalp Stimulating SerumAlso: KeraFactor Scalp Stimulating Serum, KeraFactor Serum, KeraFactorParticipants assigned to receive the active scalp-stimulating serum will apply one full dropper directly to the scalp once daily and massage it in gently. The product should not be rinsed off. In the combination treatment arm, the serum will be applied immediately before use of the Revian Red Cap. | Other | Scalp Stimulating Serum + Revian Red Cap, Scalp Stimulating Serum Only |
| Red Light Hair Growth CapAlso: Revian Red Hair Growth System, Revian Red Cap, Revian Red Wireless Smart Cap DeviceParticipants assigned to use the Revian Red Cap will use the device once daily for 10 minutes at a convenient time. The device should be used indoors or in a cool, dry area and only on dry or towel-dried hair. Study staff will assist with unboxing, app registration, and device training at the baseline visit. Device use will be logged through the Revian app. | Device | Placebo Solution + Revian Red Cap, Scalp Stimulating Serum + Revian Red Cap |
| Placebo scalp-stimulating serumAlso: Placebo scalp serum, Placebo solutionParticipants assigned to receive placebo serum will apply one full dropper directly to the scalp once daily and massage it in gently. The placebo product should not be rinsed off. The placebo serum will be identical in appearance and packaging to the active serum and labeled with coded identifiers to maintain blinding. | Other | Placebo Comparator, Placebo Solution + Revian Red Cap |
Primary outcome
Hair Density
Time frame: Baseline to 6 months
Change in hair density, measured as hairs per cm², using AI HairMetrix analysis. Measurements will be compared from baseline to follow-up visits across treatment arms.
Hair Fiber Diameter
Time frame: Baseline to 6 months
Change in average hair fiber diameter, measured in micrometers, using AI HairMetrix analysis. Measurements will be compared from baseline to follow-up visits across treatment arms.
Interfollicular Distance
Time frame: Baseline to 6 months
Change in interfollicular distance using AI HairMetrix analysis. Measurements will be compared from baseline to follow-up visits across treatment arms.
Terminal-to-Vellus Hair Ratio
Time frame: Baseline to 6 months
Change in terminal-to-vellus hair ratio using AI HairMetrix analysis. Measurements will be compared from baseline to follow-up visits across treatment arms.
4 secondary outcomes
Ludwig-Savin Scale for Women
Time frame: Baseline to 6 months
Hair Life Quality Index
Time frame: Baseline to 6 months
Hair-Q: Satisfaction with Hair
Time frame: Baseline to 6 months
Incidence and Severity of Adverse Events
Time frame: Baseline through Week 24
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
Related trials for Androgenic Alopecia
Not yet recruitingPhase 2
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
Androgenetic Alopecia
Not yet recruitingPhase 3
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Not yet recruiting
Study to Evaluate Xtressé Gummy Supplement in Women With Thinning Hair
Androgenetic Alopecia
Not yet recruitingEarly Phase 1
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
Androgenic Alopecia
Not yet recruitingPhase 3
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Scalp Stimulating Serum and Red Light Hair Growth Cap in people with Androgenic Alopecia and Female Pattern Hair Loss, run by K. Kay Durairaj, MD, FACS, A Medical Corporation at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hair Density (time frame: Baseline to 6 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.